Q1 2018 EPS Estimates for Impax Laboratories Inc Lifted by Analyst (IPXL)

Impax Laboratories Inc (NASDAQ:IPXL) – Research analysts at Leerink Swann lifted their Q1 2018 earnings estimates for shares of Impax Laboratories in a note issued to investors on Thursday. Leerink Swann analyst A. Fadia now forecasts that the specialty pharmaceutical company will post earnings of $0.28 per share for the quarter, up from their prior estimate of $0.19. Leerink Swann has a “Outperform” rating and a $22.00 price objective on the stock. Leerink Swann also issued estimates for Impax Laboratories’ Q2 2018 earnings at $0.35 EPS, Q3 2018 earnings at $0.39 EPS and Q4 2018 earnings at $0.39 EPS.

IPXL has been the subject of several other reports. UBS Group increased their price target on shares of Impax Laboratories from $12.00 to $16.00 and gave the stock a “sell” rating in a research note on Monday, October 30th. Cantor Fitzgerald set a $35.00 price target on shares of Impax Laboratories and gave the stock a “buy” rating in a research note on Friday, December 15th. BidaskClub upgraded shares of Impax Laboratories from a “sell” rating to a “hold” rating in a research note on Friday. Canaccord Genuity set a $19.00 price target on shares of Impax Laboratories and gave the stock a “hold” rating in a research note on Tuesday, October 17th. Finally, Zacks Investment Research lowered shares of Impax Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $19.62.

Impax Laboratories (NASDAQ IPXL) opened at $20.80 on Monday. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32. The stock has a market cap of $1,540.00, a PE ratio of -3.33, a P/E/G ratio of 1.07 and a beta of 0.94. Impax Laboratories has a 12 month low of $7.75 and a 12 month high of $25.70.

Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The business had revenue of $206.40 million during the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. The company’s revenue for the quarter was down 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.37 EPS.

A number of hedge funds have recently made changes to their positions in the stock. Maverick Capital Ltd. grew its position in Impax Laboratories by 6,705.5% during the 2nd quarter. Maverick Capital Ltd. now owns 7,159,336 shares of the specialty pharmaceutical company’s stock valued at $115,265,000 after purchasing an additional 7,054,136 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Impax Laboratories by 9.1% during the 2nd quarter. Vanguard Group Inc. now owns 6,821,118 shares of the specialty pharmaceutical company’s stock valued at $109,820,000 after acquiring an additional 569,723 shares during the last quarter. Fosun International Ltd boosted its holdings in shares of Impax Laboratories by 1,185.0% during the 3rd quarter. Fosun International Ltd now owns 3,854,995 shares of the specialty pharmaceutical company’s stock valued at $78,256,000 after acquiring an additional 3,554,995 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Impax Laboratories by 23.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,244,580 shares of the specialty pharmaceutical company’s stock valued at $52,238,000 after acquiring an additional 607,503 shares during the last quarter. Finally, GW&K Investment Management LLC boosted its holdings in shares of Impax Laboratories by 147.5% during the 4th quarter. GW&K Investment Management LLC now owns 1,859,924 shares of the specialty pharmaceutical company’s stock valued at $30,968,000 after acquiring an additional 1,108,348 shares during the last quarter. 90.48% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Q1 2018 EPS Estimates for Impax Laboratories Inc Lifted by Analyst (IPXL)” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/29/q1-2018-eps-estimates-for-impax-laboratories-inc-lifted-by-analyst-ipxl.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Earnings History and Estimates for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply